Skip to Main Content

For the past two years, Sarah Benoit has been getting around with the help of a walker, waiting for a medicine that’s out of reach.

Benoit, a former congressional aide, has ALS, a fatal neurological disease that gradually causes muscle weakness and paralysis. As it progresses, she struggles to maintain a normal life, but holds out hope that a drug called Radicava — the first new treatment in 22 years — will slow her deterioration.


Unfortunately, she can’t get the medicine, even though her doctor prescribed it last fall.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • We now know that ALS is caused by a bacterial infection . Borrelia and possibly co-infections. A provocative antibiotics test has been developed to demonstrate the presence of the bacteria. Commercial laboratories do not not have the appropriate antigens to detect Borrelia. Specialty laboratories should be used.
    Go to latest developments at
    Once the bacteria is detected then the Pulsed treatment method should be used.

  • This world is really cruel, I am dying and these people are laughing and thinking about my money instead of my life, I am just seeing what will happen next, which member of my body will be diagnosed next. Over in Afghanistan, I have 1,00 USD salary which is equal to 6,000 thousand Afgahani, how can I get 145,000 USD to pay for my treatment, shame on you Americans and the company who is producing the Radicava, you people are always talking about Human Rights, so where are my rights and your.

  • ““Or if the FDA uses a broader scope for approval, we may still disagree and say we’re not going to pay for it that way. FDA approval is a first step, but only one step.

    “That said, I think our approach to the whole health care system in the U.S. sucks. In a different setting that’s not so profit driven, the rationale would be different and you’d have a different answer” for Radicava, he continued. “But it’s a money-driven system.””

    What a scoundrel. He blames the “money driven system” – but it is precisely his company’s drive for money and profit that he thinks he can decide to reject the labeling criteria that the FDA decided. These insurance companies should NOT have the power to overrule the FDA and its decisions on what medicines are approved and for what patients.

  • Please fact check. Edaravone is a 17 year old product. It’s a repurposed Drug and there were no US r and D costs. The payers are restricting because it failed to work in a larger more ill population with ALS. The failed trials are J16, J17 and J 18. The data is published. The drug is generic in most of the world including Japan. It does not cost $38,000 in Japan. More like 12k for brand and under 5 k for generic. The als Association gets money from the drug company and they refuse to expose this. It’s just like the whole Marathon issue. The drug has been shown to work in less than 7 percent of people with ALS.

    It’s been indicated in Japan for 4 years. Where’s the post marketing data? The company has already made over 2 billion on this product for acute stroke.

    Please go back and get the facts. They are preying in a vulnerable population with ALS. Why is ALSA not doing their job ?

    • Hi Janice,

      Thanks for your note.

      As the story noted, the drug was approved in Japan more than a decade ago for another purpose.

      The trial focused on patients in an earlier stage of disease – there is no evidence one way or the other that it could not help people in a later stage of the disease, which the story also noted. As for the cost, that is the information I have at present.

      As for the ALS Association, the organization has told me about its concerns with the cost of the drug in the U.S. The comments from the executive director, while critical of insurers, also refers to the underlying price that is causing problems for some patients. I have updated the story to note that MT Pharma provides funding.

      I have spoken to association personnel in different parts of the country who were also concerned about the cost, not just insurance denials, and they were helpful directing me toward people who were having difficulty obtaining the drug.

      As to your question about post-marketing data, I do know the FDA approval requires the company to submit a follow up study on all ALS patients in 2022. I will ask about data from Japan.

      Thanks for writing in,
      ed at pharmalot

  • Most ALS patients who take the DP slow down the progression of their disease. As soon as Radicava is stopped the disease accelerates. The DP is cheap and over the counter.
    Further ALS is caused by a bacterial infection that is very difficult to detect. All should be on appropriate antibiotics to cover stages of the bacterial reproduction and it’s location. This has been proven with my daughter.

    • Conclusions
      Mitochondrial dysfunction, glutamate excitotoxicity,
      and oxidative stress have all been implicated in ALS
      pathogenesis, and targeting these mechanisms indi-
      vidually or by a cocktail such as the Deanna Proto-
      col could play a role in future ALS therapies.
      However, many of the preclinical and animal studies
      related to these pathways have not translated into
      successful treatments in patients with ALS. While
      there are anecdotal reports of improvements in
      patients with ALS on the Deanna Protocol, there is
      no convincing objective evidence of benefi t yet.
      Thus, at this time, ALSUntangled does not recom-
      mend the Deanna Protocol to patients with ALS.

Comments are closed.